Sinopharm Medicine (02410) Three innovative drug research results included in the 2025 ESMO conference

According to the Wisdom Financial APP, Tongyuan Health Medicine (02410) announced today that the Phase I clinical trial results of three innovative drugs independently developed by the company - CDK2/4 inhibitor TY-00540, CDK7 inhibitor TY-2699a, and CDK4/6 inhibitor TY-302, have been officially included in the poster form at the 2025 European Society for Medical Oncology (ESMO) Congress. The detailed data will be presented during the conference and published simultaneously in the ESMO official journal "Annals of Oncology". As one of the most influential academic conferences in the global oncology field, this inclusion signifies the international academic community's recognition of the early clinical value of these three drugs.